BALZERS, Liechtenstein & JINJU, South Korea--(BUSINESS WIRE)--#Artilysin--South Korean KOSDAQ listed AMICOGEN Inc. will become the latest shareholder in Lysando AG. The transaction includes an acquisition of shares, a cash contribution to Lysando and a share package to Lysando into AMICOGEN.

The deal means an 8% participation of AMICOGEN into Lysando and 2.69% in shares for Lysando into AMICOGEN. The transactions were negotiated with a 300 Mio. Euro evaluation of Lysando.

Other shareholders of Lysando continue to be majority owner and Chairman of the Board Markus Graf Matuschka von Greiffenclau, Bangkok based SCG, and Lysando�s employees.

The companies have already a productive partnership in place, based on Lysando�s leading platform Artilysin^�. It is a globally patented, sustainable and highly effective technology, fighting resistance of microbes, as an alternative to antibiotics and other antimicrobial treatments.

�I am very happy and proud to welcome AMICOGEN as a new shareholder of Lysando. AMICOGEN being such a strong and successfully operating CDMO, Asian markets, in particular China and South Korea, can now be approached faster and with the highest level of sufficiency. Our microbiome-friendly Artilysin^�-platform has incredible potential for the benefit of humanity, pets, farmed animals and the environment which can be implemented even better now�, says Lysando�s chairman Markus Graf Matuschka von Greiffenclau.

�Global spreading resistance and our increasing knowledge about the importance of a balanced microbiome require innovation and a new way of thinking. We had been impressed with the potential of Artilysin^� from the very beginning. I am looking very much forward pushing our partnership to the next level, intensifying our company�s interfaces and therefore merge know-how to even further drive the success and growth of the Artilysin^�-platform.�, says Yong Chul Shin, CEO of AMICOGEN.

Amicogen Inc.

Amicogen Inc., 092040:KOSDAQ develops, produces and markets specialty enzymes and functional food ingredients. The company offers special biocatalysts, enzyme-based new functional materials, health foods, and consumer products.

Lysando AG

Lysando AG is market-leader for antimicrobial proteins, so-called Artilysin^�s.

Artilysin^�s are a new class of molecules showing a high resistance stability and are microbiome- and environmentally-friendly. Artilysin^�s can be employed in all fields, bacteria present a problem like Medical Devices, Human Pharmaceutics, Animal Health and Consumer Care.

Contacts

Company
Lysando AG

Verena Schossmann

+41(0)79-211-83-42

[email protected]

Media
Three Winters GmbH

Prof. Wolfram Winter

+49(0)171-2345-515

[email protected]